JP2007509950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509950A5 JP2007509950A5 JP2006538195A JP2006538195A JP2007509950A5 JP 2007509950 A5 JP2007509950 A5 JP 2007509950A5 JP 2006538195 A JP2006538195 A JP 2006538195A JP 2006538195 A JP2006538195 A JP 2006538195A JP 2007509950 A5 JP2007509950 A5 JP 2007509950A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- hepatitis
- virus
- cytochrome
- protease inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 18
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 3
- 108700012707 hepatitis C virus NS3 Proteins 0.000 claims 17
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims 14
- 238000000034 method Methods 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 9
- 108010044467 Isoenzymes Proteins 0.000 claims 6
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 claims 4
- 239000003443 antiviral agent Substances 0.000 claims 3
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229960000311 ritonavir Drugs 0.000 claims 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical group N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 claims 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 229940121708 Oxygenase inhibitor Drugs 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 102000007501 Thymosin Human genes 0.000 claims 1
- 108010046075 Thymosin Proteins 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 claims 1
- 229960004285 fomepizole Drugs 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229960004125 ketoconazole Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003650 oxygenase inhibitor Substances 0.000 claims 1
- -1 polymerase Proteins 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 1
- 229960005311 telbivudine Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 claims 1
- 229960005041 troleandomycin Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51485303P | 2003-10-27 | 2003-10-27 | |
| PCT/US2004/035549 WO2005042020A2 (en) | 2003-10-27 | 2004-10-27 | Combinations for hcv treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509950A JP2007509950A (ja) | 2007-04-19 |
| JP2007509950A5 true JP2007509950A5 (enExample) | 2008-07-03 |
Family
ID=34549356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538195A Pending JP2007509950A (ja) | 2003-10-27 | 2004-10-27 | Ｈｃｖ処置の組合せ剤 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20060003942A1 (enExample) |
| EP (1) | EP1677827B1 (enExample) |
| JP (1) | JP2007509950A (enExample) |
| KR (1) | KR20060120162A (enExample) |
| CN (1) | CN1893978A (enExample) |
| AT (1) | ATE416789T1 (enExample) |
| AU (1) | AU2004285503A1 (enExample) |
| BR (1) | BRPI0415935A (enExample) |
| CA (1) | CA2543696A1 (enExample) |
| CY (1) | CY1110176T1 (enExample) |
| DE (1) | DE602004018363D1 (enExample) |
| DK (1) | DK1677827T3 (enExample) |
| ES (1) | ES2319775T3 (enExample) |
| IL (1) | IL175211A0 (enExample) |
| MX (1) | MXPA06004723A (enExample) |
| NO (1) | NO20062428L (enExample) |
| PL (1) | PL1677827T3 (enExample) |
| PT (1) | PT1677827E (enExample) |
| RU (1) | RU2006118359A (enExample) |
| SI (1) | SI1677827T1 (enExample) |
| WO (1) | WO2005042020A2 (enExample) |
| ZA (1) | ZA200603863B (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ298749B6 (cs) | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| TW201127828A (en) | 2003-09-05 | 2011-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| RU2373923C2 (ru) * | 2004-06-08 | 2009-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтические композиции |
| WO2006130553A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors |
| CN101277950B (zh) * | 2005-08-02 | 2013-03-27 | 弗特克斯药品有限公司 | 丝氨酸蛋白酶抑制剂 |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| CN101460166B (zh) * | 2006-03-06 | 2014-11-19 | Abbvie公司 | 用于治疗c型肝炎病毒的利托那韦组合物及其用途 |
| US20070225297A1 (en) | 2006-03-16 | 2007-09-27 | Perni Robert B | Deuterated hepatitis C protease inhibitors |
| US20070218138A1 (en) * | 2006-03-20 | 2007-09-20 | Bittorf Kevin J | Pharmaceutical Compositions |
| WO2007111866A2 (en) * | 2006-03-23 | 2007-10-04 | Schering Corporation | Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto |
| UA100666C2 (uk) | 2006-04-11 | 2013-01-25 | Новартіс Аг | Інгібітори нсv/віл та їх застосування |
| WO2007149382A2 (en) * | 2006-06-19 | 2007-12-27 | The Cleveland Clinic Foundation | Therapeutic compositions and methods useful in treating hepatitis |
| PT2049506E (pt) | 2006-07-07 | 2015-10-09 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de agentes terapêuticos |
| EP2112925A4 (en) * | 2006-11-15 | 2013-01-09 | Abbott Lab | SOLID PHARMACEUTICAL DOSAGE FORMULATIONS |
| EP2134717A2 (en) * | 2007-02-27 | 2009-12-23 | Vertex Pharmceuticals Incorporated | Inhibitors of serine proteases |
| MX2009009182A (es) * | 2007-02-27 | 2009-09-04 | Vertex Pharma | Co-cristales y composiciones farmaceuticas que los comprenden. |
| TWI448457B (zh) * | 2007-07-06 | 2014-08-11 | Gilead Sciences Inc | 治療劑的藥物動力學性質之調節劑 |
| NZ583699A (en) * | 2007-08-30 | 2012-04-27 | Vertex Pharma | Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same |
| US20090082366A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
| AU2008309589B2 (en) | 2007-10-10 | 2012-07-05 | Novartis Ag | Spiropyrrolidines and their use against HCV and HIV infection |
| ES2607814T3 (es) * | 2008-02-28 | 2017-04-04 | Abbvie Inc. | Preparación de tabletas |
| CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
| MX2011006333A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| US8314135B2 (en) * | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| WO2010091413A1 (en) * | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8242156B2 (en) * | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US9339531B2 (en) | 2009-02-26 | 2016-05-17 | The Johns Hopkins University | Recognition of CYP2E1 epitopes |
| US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8101643B2 (en) * | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| RU2541571C2 (ru) * | 2009-04-15 | 2015-02-20 | Эббви Инк. | Противовирусные соединения |
| RS57501B1 (sr) * | 2009-04-25 | 2018-10-31 | Hoffmann La Roche | Postupci za poboljšanje farmakokinetike |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| UA118080C2 (uk) * | 2009-06-11 | 2018-11-26 | Еббві Айрленд Анлімітед Компані | Противірусні сполуки |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| WO2010148006A1 (en) * | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) * | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) * | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) * | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011031904A1 (en) * | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| US8653070B2 (en) * | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EA201201031A1 (ru) | 2010-01-25 | 2013-02-28 | Энанта Фармасьютиклз, Инк. | Ингибиторы вируса гепатита с |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8178531B2 (en) * | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US8623814B2 (en) * | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| KR20120124495A (ko) * | 2010-03-04 | 2012-11-13 | 이난타 파마슈티칼스, 인코포레이티드 | Ｈｃｖ 복제의 억제제로서의 조합 제약 작용제 |
| UY33312A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidato de nucleosido de purina |
| EP2555622A4 (en) | 2010-04-09 | 2013-09-18 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| EP2603080A4 (en) * | 2010-08-12 | 2014-01-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| AU2011311880B2 (en) | 2010-10-08 | 2014-07-24 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
| PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| JP5669984B2 (ja) | 2011-05-18 | 2015-02-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | ５−アザスピロ［２．４］ヘプタン−６−カルボン酸およびその誘導体の製造方法 |
| RU2013155713A (ru) | 2011-07-06 | 2015-08-20 | Профибрикс Бв | Составы для лечения ран |
| AU2012308295B2 (en) | 2011-09-16 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating HCV |
| WO2013053657A1 (en) * | 2011-10-10 | 2013-04-18 | F. Hoffmann-La Roche Ag | Antiviral compounds |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| SE1450130A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| EP2583680A3 (en) | 2011-10-21 | 2013-06-12 | Abbvie Inc. | Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| AU2013262416B2 (en) * | 2012-05-18 | 2017-05-11 | Replicor Inc. | Oligonucleotide chelate complex-polypeptide compositions and methods |
| JP2015522022A (ja) * | 2012-06-27 | 2015-08-03 | アッヴィ・インコーポレイテッド | Ｈｃｖの処置に使用するためのａｂｔ−４５０およびリトナビルおよび例えばａｂｔ−０７２および／またはａｂｔ−３３３の併用処置 |
| MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| IL310969A (en) * | 2015-06-30 | 2024-04-01 | Eiger Group Int Inc | Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| AU2020312735A1 (en) * | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| WO2024223797A1 (en) | 2023-04-28 | 2024-10-31 | Institut National de la Santé et de la Recherche Médicale | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| CN101624391A (zh) * | 2001-06-11 | 2010-01-13 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
| CA2532664A1 (en) * | 2003-07-18 | 2005-01-27 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| TW201127828A (en) * | 2003-09-05 | 2011-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| AU2004282148A1 (en) * | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US7365092B2 (en) * | 2003-10-10 | 2008-04-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
-
2004
- 2004-10-27 JP JP2006538195A patent/JP2007509950A/ja active Pending
- 2004-10-27 MX MXPA06004723A patent/MXPA06004723A/es active IP Right Grant
- 2004-10-27 PL PL04810032T patent/PL1677827T3/pl unknown
- 2004-10-27 CA CA002543696A patent/CA2543696A1/en not_active Abandoned
- 2004-10-27 RU RU2006118359/15A patent/RU2006118359A/ru not_active Application Discontinuation
- 2004-10-27 US US10/974,538 patent/US20060003942A1/en not_active Abandoned
- 2004-10-27 KR KR1020067010372A patent/KR20060120162A/ko not_active Ceased
- 2004-10-27 EP EP04810032A patent/EP1677827B1/en not_active Expired - Lifetime
- 2004-10-27 WO PCT/US2004/035549 patent/WO2005042020A2/en not_active Ceased
- 2004-10-27 ES ES04810032T patent/ES2319775T3/es not_active Expired - Lifetime
- 2004-10-27 CN CNA200480037505XA patent/CN1893978A/zh active Pending
- 2004-10-27 DK DK04810032T patent/DK1677827T3/da active
- 2004-10-27 BR BRPI0415935-7A patent/BRPI0415935A/pt not_active IP Right Cessation
- 2004-10-27 SI SI200431034T patent/SI1677827T1/sl unknown
- 2004-10-27 ZA ZA200603863A patent/ZA200603863B/en unknown
- 2004-10-27 AT AT04810032T patent/ATE416789T1/de active
- 2004-10-27 DE DE602004018363T patent/DE602004018363D1/de not_active Expired - Lifetime
- 2004-10-27 PT PT04810032T patent/PT1677827E/pt unknown
- 2004-10-27 AU AU2004285503A patent/AU2004285503A1/en not_active Abandoned
-
2006
- 2006-04-26 IL IL175211A patent/IL175211A0/en unknown
- 2006-05-29 NO NO20062428A patent/NO20062428L/no not_active Application Discontinuation
-
2009
- 2009-03-10 CY CY20091100274T patent/CY1110176T1/el unknown
- 2009-06-23 US US12/490,196 patent/US20100015090A1/en not_active Abandoned
-
2012
- 2012-01-23 US US13/355,638 patent/US20120114604A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509950A5 (enExample) | ||
| RU2006118359A (ru) | Комбинации для лечения вирусного гепатита с (hcv) | |
| ES2683736T3 (es) | Procedimientos para mejorar la farmacocinética | |
| JP2008518943A5 (enExample) | ||
| RU2007105354A (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
| KR20070085547A (ko) | Ｖｘ-950을 함유한 투여 형태 및 이의 투약 계획법 | |
| JP2005524632A5 (enExample) | ||
| EA200701869A1 (ru) | Пептидомиметические ингибиторы протеазы | |
| Paeshuyse et al. | Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin | |
| KR20120139699A (ko) | Ｃ형 간염 바이러스 감염의 치료 요법 | |
| Asselah et al. | Optimal IFN‐free therapy in treatment‐naïve patients with HCV genotype 1 infection | |
| JP2010528013A5 (enExample) | ||
| Cholongitas et al. | Novel therapeutic options for chronic hepatitis C | |
| EP2809334A1 (en) | Once daily treatment of hepatitis c with ribavirin and taribavirin | |
| McHutchison et al. | Future trends in managing hepatitis C | |
| AU2007270386A1 (en) | Prophylactic or therapeutic agent for viral disease | |
| JP2015526504A (ja) | Ｈｃｖの大環状プロテアーゼ阻害剤と、非ヌクレオシドｈｃｖ阻害剤と、リトナビルとの組み合わせ | |
| Enomoto et al. | Emerging antiviral drugs for hepatitis C virus | |
| WO2015095572A1 (en) | Methods for treating liver transplant recipients | |
| Reviriego | Asunaprevir | |
| Haznedar et al. | 753 IMPACT OF LOW DOSE RITONAVIR BOOSTING ON THE PHARMACOKINETICS OF RG7227 (ITMN-191), A HIGHLY POTENT AND SELECTIVE INHIBITOR OF THE HCV NS3/4A PROTEASE | |
| Abd-Elkhalek et al. | Evolution of treatment of chronic hepatitis C virus infection by directly acting antiviral therapeutics: A glimmer of hope | |
| van Soest et al. | New treatment options for chronic hepatitis C | |
| HK1098357A (en) | Combinations for hcv treatment | |
| HAYASHI et al. | Interferon Therapy and New Antiviral Drugs for Chronic Hepatitis C |